Close Menu

NEW YORK ─ Alva, UK-based Omega Diagnostics said on Thursday that is has received CE marking for Mologic's COVID-19 lateral flow antibody test and will market the assay under Omega's Visitect brand.

The lateral flow antibody test developed by Bedford, UK-based Mologic is a point-of-care assay that detects IgA, IgG, and IgM antibodies. The test, which was independently validated by the Liverpool School of Tropical Medicine and St George's and the University of London, will be implemented in primary care settings, such as general practitioner surgeries, Omega said.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.